TAR-210 results demonstrate a 90% recurrence free survival and complete response in patients with bladder cancer

Johnson & Johnson announces their updated results from the multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer with select FGFR alterations.

“Advancement in the treatment landscape of high- or intermediate-risk non–muscle-invasive bladder cancer has remained stagnant for more than 50 years,” said Antoni Vilaseca,* M.D., Ph.D., of the Hospital Clínic de Barcelona, presenting author of the Phase 1 TAR-210 study. “Results presented today further underscore that TAR-210 for the localized treatment of bladder cancer may offer a promising alternative for patients with limited treatment options.”

The most common treatment was Grade 1/2 lower urinary tract events. There were no dose-limiting toxicities and no deaths. Two patients discontinued the study due to TEAEs of low-grade urinary symptoms and two patients had serious TEAEs with pyelonephritis and sepsis or UTI and sepsis, respectively.

FGFR genetic alterations are most common in NMIBC,” said Sabine Brookman-May, M.D., Vice President, Late Development Oncology, Johnson & Johnson Innovative Medicine. “These results further support the potential of TAR-210 with quarterly administration as a bladder-sparing and BCG-free treatment option, underscoring our deep commitment to pioneering novel therapies for patients who face limited treatment avenues.”


Related Topics and Keywords

, ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy